![]() |
|
|
Vol. 280, Issue 2, 669-676, 1997
Department of Physiology,
| |
Abstract |
|---|
|
|
|---|
The antibiotic nitrofurantoin is transported against an electrochemical gradient into milk.A monolayer of CIT3 cells, a subline of the Comma 1D normal mouse mammary epithelial cell line, transports [14C]-nitrofurantoin against a concentration gradient from the basal to the apical solution when grown on membrane filters. In a side-by-side diffusion chamber with well-stirred solutions on both sides, the transfer rate is 50% higher in the basal-to-apical than in the apical-to-basal direction. Nonlabeled nitrofurantoin (500 µM) in the basal chamber equalized the transport in both directions, suggesting that a specific transporter is responsible for the basal-to-apical increment in flux. From inhibition studies, the apparent affinity of this transporter for nitrofurantoin is 50 µM. Changes in pH between 6.4 and 7.8 had no effect on the active transport component of the flux but did affect the passive flux component. Passive flux of the nonionized molecule was 2.6 times faster than that of the ionized molecule, but the ionized molecule did appear to cross the membrane passively. Our findings show that nitrofurantoin is actively transported across a mammary epithelial cell monolayer by a transporter whose affinity for nitrofurantoin does not depend on the anionic charge on nitrofurantoin. The pH dependence of a parallel passive pathway suggests that both nonionized and ionized forms of nitrofurantoin cross the membranes of the mammary epithelial cell by passive diffusion.
| |
Introduction |
|---|
|
|
|---|
The steady-state concentration of
the antibiotic nitrofurantoin in rat milk has been shown to be much
higher than predicted on the basis of its protein binding and lipid
solubility and the pH difference between plasma and milk (Kari et
al., 1997
). We postulated that the mammary epithelium contains an
active transporter responsible for this phenomenon. However,
preliminary studies utilizing mammary gland explants failed to reveal
any active accumulation of the drug (Kari, unpublished data). We
therefore turned to CIT3 cells (Danielson et
al., 1984
). This line was selected for its ability to form tight
junctions when grown as a monolayer on a filter support. Initial
studies, carried out with membrane filters placed in a tissue culture
well, show that 1) transport from the basal to the apical solution was
much faster than transport in the opposite direction, 2) a
concentration gradient could be established between the apical and the
basal solutions and 3) basal-to-apical, but not apical-to-basal,
transport of [14C]-nitrofurantoin was inhibited by
nonlabeled nitrofurantoin. To verify that the apparent active transport
of nitrofurantoin across CIT3 cells on membrane filters is
not due to artifacts of that system and to examine the effects of pH
more systematically, we studied nitrofurantoin flux in a side-by-side
diffusion chamber in which the filter support with the cell monolayer
is placed vertically and separates well-stirred solutions (Hidalgo and
Hillgren, 1992
). We show that in this system, as in the transwell
system, there are three components to the nitrofurantoin flux. A
specific flux component is inhibited by nonlabeled nitrofurantoin and
is observed only in the basal-to-apical direction. Nonspecific flux components can be divided into a fluid phase component whose transfer coefficient is presumed to be equivalent to that of mannitol and a
diffusional component assumed to represent passive transfer across
apical and basal membranes. We show that only the latter is affected by
changes in pH between 6.4 and 7.8.
The results of studies in both membrane filter and diffusion chamber systems demonstrate active transport of nitrofurantoin across a mammary cell monolayer. This is the first report of a tissue culture model system that demonstrates active drug transport across a mammary epithelium in vitro.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals
The following drugs and chemicals were used in this study: nitrofurantoin [N-(5-nitro-2-furfurylidene)-1-aminohydantoin]; furazolidone [3-(5-nitrofurfurylideneamino)-2-oxazolidinomne] (Sigma Chemical Co., St. Louis, MO), radiolabeled nitrofurantoin (14C, methylene bridge-labeled; 97% radiopure; specific activity = 58.9 mCi/mmol) (Chemsyn Science Laboratories, Lexena, KA) and [3H]-mannitol (30 Ci/mmol) (New England Nuclear, Boston, MA).
Culture Media
For cell growth, Dulbecco's Modified Eagle's Medium (DMEM) with Ham's F12 (50:50) was supplemented with 2% heat-inactivated fetal bovine serum (FBS), 5 ng/ml epidermal growth factor (EGF), 10 µg/ml insulin, 100 U/ml penicillin and 100 µg/ml streptomycin. To differentiate the cells, this growth medium was modified by removal of EGF and addition of 3 µg/ml each of ovine prolactin (National Hormone and Pituitary Program, Rockville, MD) and hydrocortisone (Sigma Chemical Co. St. Louis, MO). The modified medium was designated the secretion medium.
Culture of CIT3 Cells
CIT3 cells.
The CIT3 cells used in
this study were derived from Comma 1D cells, a normal mouse mammary
cell line that synthesizes casein in response to prolactin (Danielson
et al., 1984
). The original Comma 1D culture was
heterogeneous and did not form a tight epithelium when grown on
appropriate filter supports. Triple trypsinizations (Schmidhauser
et al., 1990
) with selection for a high junctional resistance when grown on filters resulted in the "CIT3"
cell line. These cells form a confluent monolayer with a
transepithelial resistance of 800 to 1500 ohm · cm2 when
grown for 2 or more weeks on collagen or polycarbonate filter supports.
They remain heterogeneous, and approximately 50% of the cells respond
to prolactin by immunocytochemistry for mouse
-casein (data not
shown).
[14C]-Nitrofurantoin Transport Experiments
Experiments on transwell filters.
Approximately 2 × 104 dpm each of [14C]-nitrofurantoin and
[3H]-mannitol were placed in the top or bottom chamber of
the culture well and maintained at 37°C in an incubator outfitted
with a platform rocker rocking at about 1 Hz. The chamber receiving the
initial radioactivity is called the donor chamber. Samples (5% of the total volume in the chamber) were pipetted from the opposite, or
receiver, chamber at hourly intervals for counting. An equal volume of
nonlabeled medium was added to this chamber to maintain hydrostatic
equilibrium. At the termination of the experiment, both chambers were
sampled. Unless otherwise stated, no nonlabeled nitrofurantoin or
mannitol was added to either chamber; from the specific activity stated
by the manufacturer, the molar concentrations in the donor chamber were
0.5 to 2.0 × 10
6 M for nitrofurantoin and 1 to
2 × 10
9 M for mannitol. The concentration of
[3H]-mannitol in the donor chamber varied no more than
10% over the course of an 8-hr experiment. The same was true for the
concentration of [14C]-nitrofurantoin when the apical
chamber served as the donor chamber. The concentration of
nitrofurantoin in the basal chamber when it served as the source of
nitrofurantoin declined about 50% over the same time period, as
expected from the high rate of transport. However, the total
[14C]-nitrofurantoin in the two chambers did not change
during the course of the experiment. These observations indicate that
binding to cells or culture dishes is not a problem at these low
concentrations of drug.
Experiments in the diffusion chamber.
For more precise
studies of transport rates under conditions where unstirred layers
could be minimized and the resistance of the monolayer determined
accurately, the cell monolayers were placed in a Costar diffusion
chamber set-up in which the filter was held vertically in such a way as
to separate two side-by-side chambers (Hidalgo and Hillgren, 1992
). The
medium used in the experiments was DMEM:F12 50:50 with no addition of
serum or hormones. The assembled chambers were placed in a heat block
to maintain the solutions at 37°C. The 5 ml of solution in each
chamber was stirred rapidly by a gas-lift arrangement utilizing 5%
CO2 and oxygen. The gas pressure was adjusted so that the
gas bubbled through the chamber at the maximal rate possible without
splashing or foaming outside of the chamber. Protein-free solutions
were necessary to avoid an unacceptable degree of foaming. Resistance was measured in this system by utilizing symmetrically placed current-passing and voltage-monitoring electrodes that provided an
analytically correct measure of transepithelial resistance. Only data
from filters with a transepithelial resistance greater than 400 ohm · cm2 before and after the experiment are presented.
The relation between resistance and mannitol flux is shown in figure
1. At resistances above 300 ohm · cm2, the
mannitol transfer coefficient (see below) was less than 14 × 10
3 cm/hr in all but one filter of those plotted here.
Data from the few filters that showed mannitol transfer coefficients
greater than this value were not used.
|
|
(1) |
2 · hr
1. Because the amount
of isotope added varied up to 2-fold from one experiment to another,
the data were normalized by defining a transfer coefficient as follows:
|
(2) |
Effect of pH on transport parameters. To examine the effect of pH on both nonspecific and specific transport, we carried out the following experiment. All solutions were equilibrated with 95% O2/5% CO2 and then adjusted to pH 7.4 before being placed in the chamber. After 1 hr for temperature equilibration, [14C]-nitrofurantoin and [3H]-mannitol were added to either the apical or the basal chamber. Isotope flux was allowed to proceed for 1 hr, samples being taken at 1, 20, 40 and 60 min. Sufficient 1 M HCl or NaOH was then added to both chambers to adjust the pH to a predetermined level. In some experiments, sufficient nonlabeled nitrofurantoin to bring the concentration to 500 µM, the highest concentration of nonlabeled nitrofurantoin possible in aqueous solution, was added to the basal chamber simultaneously with the pH change. The experiment was allowed to proceed for another hour, samples being taken at 80, 100 and 120 min from the start. The transepithelial resistance was measured with Ag · AgCl electrodes in each chamber; then the solutions were removed and the pH measured. The pH was within 0.2 unit of the anticipated pH. In separate experiments, we found that pH could be maintained only if both chambers were buffered to the same pH and that, in any case, the epithelium slowly buffered the pH back to 7.4. For this reason, we limited experiments with pH changes to 1 hr and averaged the initial and final pH values in reporting the results.
[14C]-nitrofurantoin quantitation in cell culture
media.
To be certain that [14C]-nitrofurantoin was
not metabolized during the course of these experiments,
CIT3 cells on a membrane filter were incubated overnight
with [14C]-nitrofurantoin. The medium was analyzed by
high-performance liquid chromatography via the methodology
described previously (Kari et al., 1997
) for unlabeled
nitrofurantoin. The outlet of the absorbance meter was connected to a
Flo-one/
radioactive monitor equipped with a 0.5-ml wet cell.
Flow-scint II was pumped at the rate of 4 ml/min. All the radioactivity
was found in the peak corresponding to authentic nitrofurantoin, which
indicates that the drug is not metabolized by the cell line even during a relatively long-term exposure.
Scintillation counting.
Radioactivity was determined by
-scintillation counting with Budget Solve (Research Products
International Corp., Mount Pleasant, IL). The windows for double-label
counting on the Beckman LS6500 instrument were set for less than 1%
3H spillover into the 14C channel and for no
more than 18.3% spillover of 14C into the 3H
channel. Automatic calculation of disintegrations per minute was used
for each sample.
| |
Results |
|---|
|
|
|---|
Transfer Across Monolayers on Transwell Filters
Figure 2 shows the 8-hr time courses of
[14C]-nitrofurantoin and [3H]-mannitol
transport from the bottom to the top chambers separated by confluent
monolayers of CIT3 cells grown on transwell filters and,
conversely, from the top to the bottom chambers of the transwells. These experiments measure basal-to-apical and apical-to-basal flux,
respectively. To compare mannitol and nitrofurantoin fluxes we plotted
the concentration of each substrate in the receiver chamber as a
fraction of that in the donor chamber. The graph shows that the change
in the concentration ratio in either direction was linear over the 8-hr
period for both substrates. Mannitol flux, which represents the sum of
transfer via the paracellular pathway and fluid phase
transcytosis, if it exists in these cells, was less than 3% of the
nitrofurantoin flux in the basal-to-apical direction (table
1) and about 14% of the flux in the apical-to-basal direction. This indicates that the great majority of the nitrofurantoin reaches the opposite chamber by passive diffusion or active transport through the cells. Figure 2A also shows that the epithelium is capable of establishing a concentration gradient of nitrofurantoin from
the apical to the basal solution. The equilibrium level of this
gradient is not known because the transfer coefficient began to decline
after 8 hr, probably as a result of acidification of the culture medium
from metabolic processes. However, a nearly 2-fold gradient was
established between the apical and basal chambers in 8 hrs.
|
|
The data in figure 2 exaggerate the difference between the actual
basal-to-apical and apical-to-basal fluxes because of the difference in
volume between the upper and lower chambers (1.5 and 2.5 ml,
respectively). The actual fluxes were calculated as transfer
coefficients as described in "Materials and Methods" (table 1). The
transfer coefficient was about 10 × 10
3 cm/hr from
apical to basal and 63 × 10
3 cm/hr from basal to
apical solution, about a 6-fold difference under the conditions of this
experiment.
If the rapid flux of nitrofurantoin across the epithelium from the
basal to the apical side is due to a specific transporter for
nitrofurantoin, the nonlabeled nitrofurantoin should compete with the
[14C]-nitrofurantoin. To test this hypothesis, we studied
[14C]-nitrofurantoin flux from basal to apical solutions
for 3 hr in the presence of varying concentrations of nonlabeled
nitrofurantoin in the basal chamber. This compound inhibited 45% of
the flux from the basal to the apical surface with an apparent
half-maximal effect at 63 µmol (fig. 3A). As shown in
figure 3B, addition of nonradioactive nitrofurantoin to the apical
surface had no effect on the flux rate. These observations are
consistent with the presence of a specific transporter for
nitrofurantoin that acts only on basal-to-apical flux in parallel with
a nonspecific pathway in both apical and basolateral membranes (see
"Discussion"). However, the observation that nonlabeled
nitrofurantoin did not reduce the nonspecific flux from the basal to
the apical chamber to the rate of the apical to basal flux suggests
that the conditions in the apical and basal chambers differ in some
respect.
|
To obtain some information about the specificity of the putative nitrofurantoin transporter, we tested the effect of the nitrofurantoin congeners furaltadone and furazolidone, at concentrations of 250 µmol, on the flux of labeled nitrofurantoin from basal to apical solutions (fig. 2C). Both were inhibitory, furaltadone inhibiting transport by about 33% and furazolidone by 31% compared with 43% inhibition by an equimolar concentration of nitrofurantoin.
Nitrofurantoin Transport Across Mammary Monolayers in the Diffusion Chamber
Cells on transwell filters may not give an accurate picture of
fluxes across an epithelial monolayer, because both unstirred fluid
layers and metabolites may alter the flux characteristics. For these
reasons, we continued our experiments utilizing the diffusion chamber
described in "Materials and Methods." The time course of
[14C]-nitrofurantoin transfer in both directions across
CIT3 monolayers mounted in the diffusion chamber is shown
in figure 4A. The flux is linear for at least the 2 hr
shown. The concentration of isotope in the donor chamber was constant
after the first sample at 1 min, which indicated rapid mixing within
the chamber and no significant loss of isotope due to adsorption to
the walls of the chamber or evaporation (data not shown). The
transfer coefficient from the basal to the apical chamber was
64.5 × 10
3 cm/hr, approximately 50% greater
than the transfer coefficient for flux from the apical to the basal
chamber, 41.7 × 10
3 cm/hr (table 2).
Addition of 500 µM nonlabelled nitrofurantoin reduced the
basal-to-apical flux such that the transfer coefficient was similar to
that in the apical-to-basal direction. Unlabeled nitrofurantoin had no
effect on apical-to-basal flux. The mean mannitol transfer coefficient
was 6 to 8 × 10
3 cm/hr, approximately 25% of the
passive nitrofurantoin transfer coefficient. It was not significantly
different in the two directions (table 2). Because mannitol does not
cross plasma membranes and its size is similar to that
ofnitrofurantoin, its passage sets an upper limit for nitrofurantoin
transfer between the cells (paracellular transfer).
|
|
Concentration Dependence of Nitrofurantoin Inhibition of [14C]-Nitrofurantoin Flux
The relatively high proportion of nonspecific transfer of
nitrofurantoin precluded a kinetic analysis of fluxes using increasing amounts of isotope. In order to compare the affinity of nitrofurantoin for the proposed specific transporter in the diffusion chamber with the
results obtained from the transwell experiment, we again examined the
concentration dependence of nitrofurantoin inhibition of isotopic flux
(fig. 5). Increasing concentrations of nonlabeled nitrofurantoin decreased the basal-to-apical transfer coefficient from
about 64 × 10
3 to 39 × 10
3
cm/hr with an inhibitor coefficient (Ki) of
about 50 µM. Because it was necessary to average over several
experiments performed on different sets of cultures, the precision of
the replicates in the diffusion chamber is not so good as that of the
transwell filters. The remainder of the flux appeared to be
nonspecific. From the mannitol transfer coefficient (table 2), the
paracellular (and transcytotic, if it exists) component would have a
transfer coefficient of about 9 × 10
3 cm/hr. We
postulate that the remaining flux component represents passive transfer
across the apical and basal plasma membranes and has a transfer
coefficient of about 30 × 10
3 cm/hr.
|
Effect of pH on Transport Parameters
Figure 6 shows the effect of pH on basal-to-apical flux in the presence and absence of 500 µM nitrofurantoin, as well as the effect on apical-to-basal flux. All curves are similar in shape and can be fit by the following equation:
|
(3) |
3
cm/hr for Ts. Ts was
assumed to be 0 for basal-to-apical flux in the presence of 500 µM
nonlabeled nitrofurantoin, as well as for apical-to-basal flux. The
validity of this assumption is supported by the data in
figures 4 and 5. The best-fitting values for TNI and TION, obtained by nonlinear fit to the mean
data at each pH value, are given in table 3. There was
no difference in the values obtained for TNI and
TION among the three curves. The nonionized compound had a passive transfer coefficient of 65 × 10
3 cm/hr, and the fully ionized compound had a passive
transfer coefficient of about 24 × 10
3 cm/hr.
Mannitol flux did not change with pH and was about one-third the flux
rate of the fully ionized compound. This is evidence that ionized as
well as nonionized nitrofurantoin passes through plasma membranes.
|
|
| |
Discussion |
|---|
|
|
|---|
In previous work, we showed that nitrofurantoin is transported
against a concentration gradient into rat milk (Kari et al., 1997
). To define the nature of the transporter, we undertook in vitro experiments with a line of normal mouse mammary cells that were selected for their ability to form tight junctions. Using transwell filters, we found that these cells transported nitrofurantoin 6 times as fast in the apical direction as in the basolateral direction. Using nonradioactive nitrofurantoin as an inhibitor, we
found that approximately 45% of the transfer from the basolateral to
the apical chamber was inhibited at high concentrations of nitrofurantoin (500 µM), whereas transfer in the opposite direction was not inhibited by the nonlabeled nitrofurantoin. Similar but not
identical results were obtained when the experiments were carried out
in a diffusion chamber. These observations are consistent with a model
(fig. 7) in which passive transfer of the drug across both apical and basal plasma membrane proceeds in parallel with an
active transport pathway.
|
These flux differences persist in a side-by-side diffusion chamber
setup where excellent stirring is possible and hydrostatic pressures on
both sides of the filter are equal at all times. In addition to making
excellent stirring possible, the diffusion chamber setup offers other
advantages: flux rates can be easily monitored by removing a small
portion of the solutions on either side of the filter at regular
intervals, and constant monitoring of transepithelial resistance is
possible. In the diffusion chamber, fluxes were linear during the
period of the experiments, and mannitol flux, which represents transfer
between the cells, averaged less than 25% of the passive flux rate
under all conditions. Furthermore, addition of 500 µM nitrofurantoin
to the solution bathing the basal surface of the cells equalized the
fluxes in the two directions. The inhibitor constant
Ki, 50 µM, was not significantly different from the inhibitor constant of 63 µM found using transwell filters. On the other hand, the apical-to-basal transfer coefficient was about
43 × 10
3 cm/hr compared with about 10 × 10
3 cm/hr in the diffusion chamber. The basal-to-apical
flux rate was 60 to 65 × 10
3 cm/hr, rather faster
than expected on the basis of the apical flux, and was reduced to 35 to
45 × 10
3 cm/hr in the presence of 500 µM
nitrofurantoin in both types of chamber. We postulate that the pH in
the restricted space below the filter in the transwell setup may be
more acidic than the rest of the solution in the chamber, thereby
enhancing passive flux from the basal to the apical solution.
It is important to understand the advantages and limitations of the transwell and diffusion chamber setups. Transwell filters have the advantage that no special equipment is necessary to study fluxes other than the tissue culture wells in which the cells are grown. Furthermore, it is possible to handle many filters in one experiment, which makes possible several replicates for each experimental condition. The fact that the Ki values for the effect of nonlabeled nitrofurantoin on the basal-to-apical flux were similar in the two setups suggests that the transwell filter system is suitable for screening inhibitors, a necessary step in determining the physiological substrate for this transporter. However, absolute flux rates cannot be determined reliably in this system, because adequate stirring may not be possible, and metabolites or hydrogen ion may build up in the limited space beneath the filter, altering the flux rates. For such determinations the diffusion chamber setup is essential, because it provides well-stirred solutions on both sides of the filter and because the volumes of solution are larger, which minimize the effect of metabolites. However, no more than six filters can be studied in a single experiment, a drawback that seriously limits the number of replicates possible at any one time.
The model shown in figure 7 illustrates three potential
paths for the transfer of nitrofurantoin across the mammary epithelium: a paracellular pathway, a passive transcellular pathway and an active
transport pathway. Transfer via the paracellular pathway was
monitored by the transfer of mannitol across the epithelial monolayer
and was uniformly low, achieving a concentration of 1% of the source
chamber in 2 hr, a result consistent with the high electrical
resistance of these monolayers. Transfer via the passive
pathway
that is, the fraction of transfer that could not be inhibited
by nonisotopic nitrofurantoin
was significant and, at the
concentration of [14C]-nitrofurantoin used in these
experiments, was of the same order of magnitude as the flux through the
active pathway. In more recent experiments, we have found that allowing
the cells to grow on the filters for the diffusion chamber for a longer
time increases the transepithelial resistance. Under these conditions,
the active portion of the flux was about double the passive flux (data
not shown).
The location of the active transporter is not clear from the present
experiments. A basal location (pump B in fig. 7) is the most
parsimonious explanation for the effects of basal inhibitors and would
suggest an analogy to the renal organic anion transporter (Pritchard
and Miller, 1992
). However, an active transporter in the apical
membrane that pumps nitrofurantoin out of the cell is also a
possibility (pump A in fig. 7). One might expect inhibition of an
apical pump with nonlabeled nitrofurantoin to increase the apical-to-basal flux rate; a slight increase was observed in the diffusion chamber (table 2).
This is the first report of active transport of a pharmaceutical agent
across a model mammary epithelium in vitro, although a
number of compounds have been found at high milk-to-plasma ratios in vivo (see Kari et al., 1997
for review). The
largest apical-to-basal ratios we have been able to achieve in the
in vitro system are about 3 at steady state, rather than the
23 observed in in vivo experiments in the rat. There are a
number of possible explanations for this observation. The most likely
is that the number of transporters per cell in the rat mammary
epithelium is greater than the number in CIT3 cells, which
increases the ratio of active to passive flux in vivo.
Another difference between the in vivo transport results and
the in vitro effects of inhibitors is that neither furazolidone nor furaltadone establishes large gradients across the rat
mammary epithelium, although they are effective inhibitors of
nitrofurantoin transport in vitro. A high milk-to-plasma
ratio requires a high ratio of active transport to passive transport at
the drug concentrations found in plasma. Possibly these analogs have a
higher passive flux rate than nitrofurantoin, such that the gradient is
dissipated. This seems quite likely for the nonpolar molecule
furazolidone. On the other hand, the affinity of the compound for the
transporter may also be lower so that active transfer is lower at
concentrations achievable in plasma.
The lack of effect of pH on the specific component of nitrofurantoin
flux was at first somewhat surprising, because we expected the putative
nitrofurantoin transporter to recognize the anionic character of this
molecule. However, Ullrich and Rumrich (1992)
have recently shown that
the charge on organic anions does not alter recognition by the renal
organic anion transporter. In agreement with this concept, we found
(Kari et al., 1997
) that both a neutral analog of
nitrofurantoin (furazolidone) and a basic analog (furaltadone) inhibited [14C]-nitrofurantoin transport to nearly the
same extent as nonlabeled nitrofurantoin. We conclude that, like the
renal organic anion transporter, the specificity of the mammary
nitrofurantoin transporter does not reside in the anionic charge on the
molecule. Inhibitor experiments to be published elsewhere suggest that,
like the renal organic anion transporter (Ullrich and Rumrich, 1992
;
Ullrich and Rumrich, 1988
) the nitrofurantoin transporter interacts
with a large variety of therapeutic agents. However, additional
experiments are necessary to determine to what extent the biology of
the nitrofurantoin transporter is, in fact, similar to that of the
renal organic anion transporter (Pritchard and Miller 1992
), and
molecular cloning (Wolff et al., 1992
) will be necessary to
determine whether nitrofurantoin transport is the result of expression
of the renal anion transporter in the mammary epithelium.
The results of these experiments were also surprising in that they show
that the ionized form of nitrofurantoin is transferred passively (or at
least at equal rates in both directions) across the mammary epithelium,
though at a slower rate than the nonionized form. We postulate that
both forms of the molecular can pass into and out of the cell by
diffusion through the plasma membrane. If the charge on the ionized
form is diffusely distributed on the molecule, then interactions with
water may be sufficiently weak that transfer into the hydrophobic
interior of the membrane is energetically feasible. If this is the
case, then the usual theoretical framework (Oo et al., 1995
;
Fleishaker and McNamara, 1988
) for calculating the milk-to-plasma ratio
must be revised. In theory, the milk-to-plasma ratio for drugs that are
passively transferred into milk takes into account entrapment of the
drug in the milk fat globule and binding of drug to plasma and milk proteins and explicitly states that only the nonionized form of the
drug is able to cross the epithelial membranes. If the ionized form of
the drug is also able to cross the mammary membranes, then the effect
of the differential in pH between milk and plasma on the milk-to-plasma
ratio will be reduced, but not eliminated.
Perspective
Our studies of the effect of pH on the transfer of nitrofurantoin into milk show that, like the renal anion transporter, the specificity of the mammary nitrofurantoin transporter does not reside in the anionic charge on the molecule. This finding and the apparent broad specificity of the transporter (Toddywalla and Neville, unpublished observations) suggest that the renal organic anion transporter or a similar molecule is present in the mammary epithelium. The easy accessibility of the tissue and our ability to characterize nitrofurantoin transport functionally suggest that expression cloning of the transporter by using mRNA from CIT3 cells is feasible. From a practical standpoint, these studies and inhibitor studies may help us predict which drugs are likely to be actively transported into milk. This information should be important both to breast-feeding mothers, some of whom must take therapeutic agents, and to dairy farmers, who are still in great need of improved antibiotic therapies against mastitis.
| |
Acknowledgements |
|---|
The authors thank Sean Gavigan, A. R. Martin, P. McNamara and J. C. Pritchard for helpful discussion and Valerie Sawicki for crucial assistance with the tissue culture techniques.
| |
Footnotes |
|---|
Accepted for publication October 3, 1996.
Received for publication July 8, 1996.
1 The work presented here was supported in part by NIH grant HD 19547 to M.C.N. and by a Research Fellowship from the World Health Organization to V.S.T.
Send reprint requests to: Margaret C. Neville, Ph.D., Department of Physiology, Box C240, University of Colorado Health Sciences Center, Denver, CO 80262.
| |
Abbreviations |
|---|
CIT3, a subline of the Comma 1D normal mouse mammary cell line; EGF, epithelial growth factor.
| |
References |
|---|
|
|
|---|
-casein 5
sequences in stably transfected mouse mammary cells.
Proc. Natl. Acad. Sci. U.S.A.,
87: 9118-9122, 1990This article has been cited by other articles:
![]() |
L. Wang, M. Leggas, M. Goswami, P. E. Empey, and P. J. McNamara N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine Carboxamide (GF120918) As a Chemical ATP-Binding Cassette Transporter Family G Member 2 (Abcg2) Knockout Model to Study Nitrofurantoin Transfer into Milk Drug Metab. Dispos., December 1, 2008; 36(12): 2591 - 2596. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fischer, H. Stuckas, M. Gluth, T. D. Russell, M. C. Rudolph, N. E. Beeman, S. Bachmann, S. Umemura, Y. Ohashi, M. C. Neville, et al. Impaired tight junction sealing and precocious involution in mammary glands of PKN1 transgenic mice J. Cell Sci., July 1, 2007; 120(13): 2272 - 2283. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Merino, J. W. Jonker, E. Wagenaar, A. E. van Herwaarden, and A. H. Schinkel The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin Mol. Pharmacol., May 1, 2005; 67(5): 1758 - 1764. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Gerk, J. A. Moscow, and P. J. McNamara BASOLATERAL ACTIVE UPTAKE OF NITROFURANTOIN IN THE CIT3 CELL CULTURE MODEL OF LACTATION Drug Metab. Dispos., June 1, 2003; 31(6): 691 - 693. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Shennan and M. Peaker Transport of Milk Constituents by the Mammary Gland Physiol Rev, July 1, 2000; 80(3): 925 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. Kari, R. Weaver, and M. C. Neville Active Transport of Nitrofurantoin Across the Mammary Epithelium In Vivo J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 664 - 668. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||